Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$681.00K$681.00Kderivedno prior Q4 2021 on file Net Income-$8.26M-$8.26Mderivedno prior Q4 2021 on file EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$9,740,000— Operating Cash Flowderived-$8,062,000— Free Cash Flowderived-$8,370,000— Margins · derivedOperating margin-1430.2%
Net margin-1212.9%
ended Dec 31, 2022 · filed Mar 6, 2023 · 65 d after period end